Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2003
10/16/2003WO2003084541A1 Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers
10/16/2003WO2003084539A2 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
10/16/2003WO2003084535A1 Antidiabetic agents
10/16/2003WO2003084533A1 N-`4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
10/16/2003WO2003084528A1 A method for reversing permeability modifications caused by acute peritonitis
10/16/2003WO2003084527A1 Severe sepsis preventive therapeutic agent
10/16/2003WO2003084525A1 Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases
10/16/2003WO2003084524A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003WO2003084521A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003WO2003084464A2 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
10/16/2003WO2003070701A3 Syntheses of quinazolinones
10/16/2003WO2003068813A3 Group b streptococcus antigen
10/16/2003WO2003062276A3 Multimers of receptor-binding ligands
10/16/2003WO2003061620A3 Peptide-carrying bodies for immune response
10/16/2003WO2003051905A3 Taojiks as modifiers of the beta-catenin pathway and methods of use
10/16/2003WO2003051393A3 Enzymatic cleavable reagents for specific delivery to disease sites
10/16/2003WO2003039439A3 Deuterated pyrazolopyrimidinones and drugs containing said compounds
10/16/2003WO2003039231A3 Compounds and methods for treating transplant rejection
10/16/2003WO2003035835A3 Glycoprotein compositions
10/16/2003WO2003033660A3 9136, a human aldehyde dehydrogenase family member and uses therefor
10/16/2003WO2003033527A3 Cyclosporine analogue mixtures and their use as immunomodulating agents
10/16/2003WO2003032969B1 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
10/16/2003WO2003026492A3 Prevention and treatment of restenosis by local administration of drug
10/16/2003WO2003022997A3 Human tissue urokinase type plasminogen activator formulation
10/16/2003WO2003015494A3 Tocopherol enriched compositions and amelioration of inflammatory symptoms
10/16/2003WO2003008407A3 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
10/16/2003WO2002100849A3 Novel nitriles useful as reversible inhibitors of cysteine proteases
10/16/2003WO2002098899A3 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/16/2003WO2002085299A3 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/16/2003WO2002084298A3 Medicaments which are modulators of hm74 and/or hm74a activity
10/16/2003WO2002076939A3 Cysteine protease inhibitors
10/16/2003WO2002064134A3 Use of calcium indomethacin for the treatment of cyclo-oxygenase 2-mediated pathologies
10/16/2003WO2002064065A3 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation
10/16/2003WO2002045705A3 Regenaration of blood vessels
10/16/2003WO2002036118A3 Heterocyclic derivatives useful as pharmaceutical agents
10/16/2003US20030196217 Desaturase genes, enzymes encoded thereby, and uses thereof
10/16/2003US20030195361 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
10/16/2003US20030195356 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
10/16/2003US20030195352 For therapy of diabetes, obesity, impaired glucose tolerance, gastrointestinal disorders, hypertriglyceridemia, hypercholesteolemia, atherosclerotic disorders, or cardiovascular disorders
10/16/2003US20030195251 For therapy of psychiatric, pain and other disorders
10/16/2003US20030195247 Antagonists of protein tryosin phosphatase 1B (PTP-1B) and T-cell protein tyrosine phosphatase (TC-PTP), used as antidiabetic agents and for prophylaxis of insulin resistance
10/16/2003US20030195246 Seamless soft capsule preparations containing dihydrobenzofuran derivatives
10/16/2003US20030195241 Mitogen-activated protein kinase inhibitors used for prophylaxis of cancer, inflammatory and cardiovascular disorders, and as coatings for medical equipments such as stents
10/16/2003US20030195238 Enzyme inhibitors
10/16/2003US20030195236 Heterocyclic imines such as 2-methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine, used for prophylaxis of vitamin B6 deficiency, cardiovascular disorders or melanomas
10/16/2003US20030195235 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/16/2003US20030195230 Substituted amine derivatives and methods of use
10/16/2003US20030195226 Nitrogen compounds such as pyridine-3-carbaldehyde, O-(((4-undecyloxy-phenyl)amino)carbonyl)oxime, used for prophylaxis of vision, eating or cardiovascular disorders, and as anxiolytic and antiemetic agents
10/16/2003US20030195222 Substituted pyrimidinones and pyrimidinthiones
10/16/2003US20030195221 Substituted indolizine-like compounds and methods of use
10/16/2003US20030195215 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors
10/16/2003US20030195212 An amide derivatives for treating obesity, anorexia, inflammation, mental diseases associated with the melanocyte stimulating hormones
10/16/2003US20030195211 Inhibitors of human phosphatidylinositol 3-kinase delta
10/16/2003US20030195210 An enzyme inhibitors of cyclic guanosine 3',5'-monophophate-metabolizing phosphodiesterases; treating cardiovascular disorders, brian disorders, Alzheimer's disease, urogenital or sexual disorders
10/16/2003US20030195206 An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis
10/16/2003US20030195202 Inhibitors of IMPDH enzyme
10/16/2003US20030195201 Vanilloid receptor ligands and their use in treatments
10/16/2003US20030195194 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis
10/16/2003US20030195193 Useful as activated blood coagulation factor X inhibitor; useful as an anticoagulant or an agent for prophylaxis and therapy of diseases caused by thrombus or embolus
10/16/2003US20030195188 Pyridine and quinoline derivatives
10/16/2003US20030195181 Laulimalide derivatives
10/16/2003US20030195179 Redispersibility comprising polyvinylpyrrolidone and a water-soluble anionic macromolecular compound which are added to prevent a hardly soluble drug from adhering to a container and forming aggregates
10/16/2003US20030195177 Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
10/16/2003US20030195172 Novel phosphonic acid compounds as inhibitors of serine proteases
10/16/2003US20030195169 Such as (S)-phosphoric acid mono-(3-(5-chloro-2-methoxy-phenyl)-3-fluoro-2-oxso-6-trifluoromethyl-2,3 -dihydro-indol-1-ylmethyl)ester; for modulation of large-conductance calcium-activated potassium (BK) channels
10/16/2003US20030195168 Comprises macrocyclic diterpene compounds from Euphorbiaceae for treatment and prophylaxis of protein kinase C (PKC) related conditions (alcoholism, Alzheimer's disease, asthma, atherosclerosis); expression inhibition; computer programs
10/16/2003US20030195160 Sodium channel blockers
10/16/2003US20030195157 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
10/16/2003US20030195146 Prepared by culturing Beauveria in medium; substances thus obtained are less toxic, specifically inhibit acyl-Coenzyme A: cholesterol acyltransferase, and inhibit formation of oil droplets in macrophages
10/16/2003US20030195145 Methods of treatment with combinations of statin and aryl-substituted propanolamine derivatives
10/16/2003US20030194802 Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
10/16/2003US20030194761 Novel nucleic acid sequences encoding human fibroblast growth factor-like polypeptides
10/16/2003US20030194746 For diagnosis, prognosis, prophylaxis
10/16/2003US20030194720 Human ion channels
10/16/2003US20030194413 Methods and compositions employing red rice fermentation products
10/16/2003US20030194398 Having serine protease inhibitory activity
10/16/2003US20030194397 Introducing platelet-rich plasma into and around the site of the injury
10/16/2003US20030194390 Alkyl cyanoacrylate and inhibitor and aggregate structure formed; alkyl fatty ester, opacifier; ablating tissue by blocking blood flow
10/16/2003US20030194389 Occlusive composition
10/16/2003US20030194375 Anti-epileptogenic agents
10/16/2003CA2481995A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003CA2481976A1 Novel thyroid receptor ligands
10/16/2003CA2481925A1 Therapeutic agent for patients having human fc.gamma.riiia
10/16/2003CA2481920A1 Antibody composition-containing medicament
10/16/2003CA2481879A1 Hydroxamic acid derivatives
10/16/2003CA2481850A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003CA2481837A1 Production process for antibody composition
10/16/2003CA2481706A1 Antidiabetic agents
10/16/2003CA2481701A1 Benzoxazinone-derived compounds, their preparation and use as medicaments
10/16/2003CA2481658A1 Method of enhancing of binding activity of antibody composition to fcy receptor iiia
10/16/2003CA2481657A1 Cells of which genome is modified
10/16/2003CA2481656A1 Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost
10/16/2003CA2481392A1 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003CA2481379A1 Medicinal composition comprising acat inhibitor and insuline resistance improving agent
10/16/2003CA2481090A1 Novel pancortin-pablo protein interactions and methods of use thereof
10/16/2003CA2481028A1 Hormone replacement therapy
10/16/2003CA2481026A1 N-`4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
10/16/2003CA2480818A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003CA2480697A1 Novel association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases
10/16/2003CA2480579A1 Embolization
1 ... 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 ... 1595